Skip to main
  1. Stocks
  2. Bio-Rad Laboratories
  3. Forecast
BIO

Bio-Rad Laboratories (BIO) Stock Forecast & Price Target

Bio-Rad Laboratories (BIO) Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Rad Laboratories is attractive because its first organic growth quarter in 2026 showed early recovery, with revenue up 0.7%, led by Clinical Diagnostics at +2.8% and improving Life Science ex-process chromatography growth of about 2.5%. Management’s restructuring and R&D rationalization, including a 17% reduction in R&D headcount and $30–$35 million of net annualized cost savings, support margin expansion toward FY26 gross margin guidance of 53%–54% and operating margin of 10%–12%. The stock also benefits from optionality in its ~33% Sartorius stake, while valuation remains reasonable at about 14x–15x EV/EBITDA versus a higher peer multiple, leaving room for rerating as headwinds fade in 2027 and beyond.

Bears say

Bio-Rad Laboratories is facing a negative outlook because investors may continue to lose confidence in its sales and margin trajectory, driving further multiple erosion and a steeper discount on its Sartorius stake, which could depress valuation under a 15x EBITDA framework. The company also faces prolonged end-market weakness in life science tools, ongoing share losses in ddPCR to Qiagen, and mixed M&A execution, all of which point to weaker organic growth and integration risk. In addition, its life science exposure to wet-lab research creates structural pressure if software and AI reduce demand, while the dual-class share structure and Schwartz family control raise governance concerns that may limit shareholder alignment.

Bio-Rad Laboratories (BIO) has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Rad Laboratories and is not a guaranteed prediction by Public.com or investment advice.

Bio-Rad Laboratories (BIO) Analyst Forecast & Price Prediction

Get the latest Bio-Rad Laboratories (BIO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Bio-Rad Laboratories (BIO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Rad Laboratories (BIO) Forecast

Analysts have given Bio-Rad Laboratories (BIO) a Hold based on their latest research and market trends.

According to 3 analysts, Bio-Rad Laboratories (BIO) has a Hold consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $366.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $366.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Rad Laboratories (BIO)


Bio-Rad Laboratories (BIO) Analyst Forecast & Price Prediction

Get the latest Bio-Rad Laboratories (BIO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Bio-Rad Laboratories (BIO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BIO stock data and trends